Form D · Biotechnology
Bonum Therapeutics, Inc.
Seattle, WA · CIK 0001898714
Offering snapshot reported Apr 17, 2026 · SEC filing
- Reported sold
- $26.9M Offering amount: $32.3M
- Investors reported
- 8 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 3, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 17, 2026 | Initial | $26,907,396 | No comparison | 8 | SEC filing |
| Nov 29, 2022 | Initial | $45,041,421 | No comparison | 10 | SEC filing |
| Dec 22, 2021 | Initial | $1,186,887 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-580902
Source: Form D, filed Apr 17, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Gaurav Aggarwal | Director |
| Samuel Bjork | Director |
| Samuel Blackman | Director |
| Karl Handelsman | Director |
| Diane Hollenbaugh | Executive |
| John Mc Kearn | Director |
| John Mulligan | Director, Executive, Promoter |
| Mitchell Mutz | Director |
| Neela Patel | Executive |
| Monique Schiersing | Director |
| Nicholas Walrod | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1150 Eastlake Avenue E Suite 1100
Seattle, WA, 98109
Seattle, WA, 98109